Chantal Csajka

List of Publications by Year
in descending order

113 papers	3,841 citations	126858 33 h-index	143943 57 g-index
118 all docs	118 docs citations	118 times ranked	5453 citing authors

#	ARTICLE	IF	CITATIONS
1	Parametric Approaches in Population Pharmacokinetics. Journal of Clinical Pharmacology, 2022, 62, 125-141.	1.0	17
2	Parametric and Nonparametric Methods in Population Pharmacokinetics: Experts' Discussion on Use, Strengths, and Limitations. Journal of Clinical Pharmacology, 2022, 62, 158-170.	1.0	9
3	High anticholinergic burden at admission associated with in-hospital mortality in older patients: A comparison of 19 different anticholinergic burden scales. Basic and Clinical Pharmacology and Toxicology, 2022, 130, 288-300.	1.2	7
4	Interventions to support adherence to oral anticancer therapies: research challenges, lessons learned, and strategies to overcome them from Australia and Switzerland. Supportive Care in Cancer, 2022, 30, 3655-3659.	1.0	1
5	Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation. Clinical Pharmacology and Therapeutics, 2022, 112, 353-363.	2.3	5
6	Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer. Pharmaceutics, 2022, 14, 1317.	2.0	3
7	Evaluation of the association of anticholinergic burden and delirium in older hospitalised patients – A cohort study comparing 19 anticholinergic burden scales. British Journal of Clinical Pharmacology, 2022, 88, 4915-4927.	1.1	6
8	Cross-cultural adaptation and psychometric validation of the revised Patients' Attitudes Towards Deprescribing (rPATD) questionnaire in French. Research in Social and Administrative Pharmacy, 2021, 17, 1453-1462.	1.5	17
9	Quality of anticholinergic burden scales and their impact on clinical outcomes: a systematic review. European Journal of Clinical Pharmacology, 2021, 77, 147-162.	0.8	47
10	Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV. Clinical Pharmacokinetics, 2021, 60, 379-390.	1.6	4
11	Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs. European Journal of Clinical Pharmacology, 2021, 77, 979-987.	0.8	2
12	Once-daily 1 g ceftriaxone optimizes exposure in patients with septic shock and hypoalbuminemia receiving continuous veno-venous hemodiafiltration. European Journal of Clinical Pharmacology, 2021, 77, 1169-1180.	0.8	6
13	Clinical and economic impacts of explicit tools detecting prescribing errors: A systematic review. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 877-886.	0.7	7
14	Optimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication Adherence Program Along With Systematic Collection and Modeling of Pharmacokinetic and Pharmacodynamic Data. JMIR Research Protocols, 2021, 10, e30090.	0.5	7
15	Ability to detect potentially inappropriate prescribing in older patients: comparative analysis between PIM-Check and STOPP/STARTv2. European Journal of Clinical Pharmacology, 2021, 77, 1747-1756.	0.8	4
16	Drug-Drug Interactions with Direct Oral Anticoagulants: Practical Recommendations for Clinicians. American Journal of Medicine, 2021, 134, 939-942.	0.6	13
17	Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation. Journal of Antimicrobial Chemotherapy, 2021, , .	1.3	2
18	Protocols for cognitive enhancement. A user manual for Brain Health Services—part 5 of 6. Alzheimer's Research and Therapy, 2021, 13, 172.	3.0	15

#	ARTICLE	IF	CITATIONS
19	Impact of Pharmaceutical Interventions in Hospitalized Patients: A Comparative Study Between Clinical Pharmacists and an Explicit Criteria-Based Tool. Current Therapeutic Research, 2021, 95, 100650.	0.5	4
20	Optimisation of vancomycin exposure in neonates based on the best level of evidence. Pharmacological Research, 2020, 154, 104278.	3.1	25
21	Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses. Clinical Pharmacokinetics, 2020, 59, 371-382.	1.6	8
22	Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review. Therapeutic Drug Monitoring, 2020, 42, 33-44.	1.0	25
23	The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib. Frontiers in Pharmacology, 2020, 11, 177.	1.6	59
24	A population pharmacokinetic model for escitalopram and its major metabolite in depressive patients during the perinatal period: Prediction of infant drug exposure through breast milk. British Journal of Clinical Pharmacology, 2020, 86, 1642-1653.	1.1	13
25	Population Pharmacokinetics of Erlotinib in Patients With Non–small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients. Clinical Therapeutics, 2020, 42, 1302-1316.	1.1	13
26	Development and validation of a multiplex UHPLC–MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV. Journal of Mass Spectrometry, 2020, 55, e4506.	0.7	22
27	Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy. Open Forum Infectious Diseases, 2020, 7, ofz464.	0.4	7
28	Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma. Cancers, 2020, 12, 931.	1.7	12
29	Influence of Drug–Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV. Clinical Pharmacokinetics, 2020, 59, 1037-1048.	1.6	5
30	UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1125, 121733.	1.2	10
31	Towards Personalized Antithrombotic Treatments: Focus on P2Y12 Inhibitors and Direct Oral Anticoagulants. Clinical Pharmacokinetics, 2019, 58, 1517-1532.	1.6	6
32	Gender medicine and oncology: report and consensus of an ESMO workshop. Annals of Oncology, 2019, 30, 1914-1924.	0.6	120
33	Population pharmacokinetics of dolutegravir: influence of drug–drug interactions in a real-life setting. Journal of Antimicrobial Chemotherapy, 2019, 74, 2690-2697.	1.3	23
34	Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence – an update. Expert Opinion on Drug Safety, 2019, 18, 949-963.	1.0	47
35	Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug–drug interactions and probability of target attainment. British Journal of Clinical Pharmacology, 2019, 85, 2022-2032.	1.1	7
36	Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence. Journal of Antimicrobial Chemotherapy, 2019, 74, 2468-2470.	1.3	3

#	ARTICLE	IF	CITATIONS
37	Population pharmacokinetics and pharmacodynamics of the artesunate–mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children. Malaria Journal, 2019, 18, 139.	0.8	10
38	Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre. Scientific Reports, 2019, 9, 5078.	1.6	71
39	Adherence to intermittent preventive treatment for malaria in Papua New Guinean infants: A pharmacological study alongside the randomized controlled trial. PLoS ONE, 2019, 14, e0210789.	1.1	3
40	Reply to L. Pala et al. Journal of Clinical Oncology, 2019, 37, 439-440.	0.8	3
41	Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general population. European Journal of Clinical Pharmacology, 2019, 75, 939-949.	0.8	2
42	Contribution of Genetic Background and Data Collection on Adverse Events of Anti–human Immunodeficiency Virus (HIV) Drugs (D:A:D) Clinical Risk Score to Chronic Kidney Disease in Swiss HIV-infected Persons With Normal Baseline Estimated Glomerular Filtration Rate. Clinical Infectious Diseases, 2019, 70, 890-897.	2.9	7
43	Polypharmacy, Drug–Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV. Open Forum Infectious Diseases, 2019, 6, ofz531.	0.4	38
44	Quantitative Analysis of Gentamicin Exposure in Neonates and Infants Calls into Question Its Current Dosing Recommendations. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	25
45	Pregnancy outcomes in women on metformin for diabetes or other indications among those seeking teratology information services. British Journal of Clinical Pharmacology, 2018, 84, 568-578.	1.1	35
46	Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1083, 124-136.	1.2	31
47	Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients. Clinical Pharmacokinetics, 2018, 57, 229-242.	1.6	21
48	Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs. Clinical Pharmacokinetics, 2018, 57, 1-6.	1.6	29
49	Sex Differences in Efficacy and Toxicity of Systemic Treatments: An Undervalued Issue in the Era of Precision Oncology. Journal of Clinical Oncology, 2018, 36, 2680-2683.	0.8	100
50	Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections. Journal of Antimicrobial Chemotherapy, 2018, 73, 3413-3422.	1.3	40
51	Determination of nucleosidic/tidic reverse transcriptase inhibitors in plasma and cerebrospinal fluid by ultra-high-pressure liquid chromatography coupled with tandem mass spectrometry. Clinical Mass Spectrometry, 2018, 8, 8-20.	1.9	10
52	Population Pharmacokinetic Study of Amoxicillin-Treated Burn Patients Hospitalized at a Swiss Tertiary-Care Center. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	9
53	Pratique de la pharmacie clinique en Suisse romande. , 2018, , 1141-1152.e3.		0
54	Simultaneous determination of selective serotonin reuptake inhibitors and their main metabolites in human breast milk by liquid chromatography-electrospray mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1057, 101-109.	1.2	19

#	Article	IF	Citations
55	Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	32
56	Pharmacometrics-based decision tools facilitate mHealth implementation. Expert Review of Clinical Pharmacology, 2017, 10, 39-46.	1.3	6
57	Association of nicotine metabolism and sex with relapse following varenicline and nicotine replacement therapy.. Experimental and Clinical Psychopharmacology, 2017, 25, 353-362.	1.3	12
58	Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study. Therapeutic Drug Monitoring, 2016, 38, 506-515.	1.0	2
59	Outbreak in meldonium positive laboratory tests: are we missing something?. British Journal of Sports Medicine, 2016, 50, 1422-1423.	3.1	4
60	Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals. Journal of Antimicrobial Chemotherapy, 2016, 71, 1933-1942.	1.3	13
61	Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates. Journal of Clinical Pharmacology, 2016, 56, 909-935.	1.0	61
62	Stereoselective determination of citalopram and desmethylcitalopram in human plasma and breast milk by liquid chromatography tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2016, 131, 233-245.	1.4	16
63	Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients. Clinical Pharmacokinetics, 2016, 55, 1521-1533.	1.6	25
64	Safety of Drugs during Pregnancy and Breastfeeding in Cystic Fibrosis Patients. Respiration, 2016, 91, 333-348.	1.2	11
65	Utility of an Algorithm to Increase the Accuracy of Medication History in an Obstetrical Setting. PLoS ONE, 2016, 11, e0151205.	1.1	1
66	Vitamin D Time Profile Based on the Contribution of Non-Genetic and Genetic Factors in HIV-Infected Individuals of European Ancestry. Antiviral Therapy, 2015, 20, 261-269.	0.6	5
67	Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence. Expert Opinion on Drug Safety, 2015, 14, 413-427.	1.0	47
68	Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort. Clinical Pharmacokinetics, 2015, 54, 1259-1272.	1.6	44
69	Improved Investigations in Drug Safety by More In-Depth Individual Pharmacokinetics Using High-Resolution Mass Spectrometry. Therapeutic Drug Monitoring, 2015, 37, 141-146.	1.0	2
70	Therapeutic drug monitoring of targeted anticancer therapy. Biomarkers in Medicine, 2015, 9, 887-893.	0.6	24
71	Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. British Journal of Clinical Pharmacology, 2014, 78, 1090-1101.	1.1	50
72	Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals. Journal of Antimicrobial Chemotherapy, 2014, 69, 2489-2498.	1.3	31

#	Article	IF	Citations
73	High-throughput hydrophilic interaction chromatography coupled to tandem mass spectrometry for the optimized quantification of the anti-Gram-negatives antibiotic colistin A/B and its pro-drug colistimethate. Journal of Chromatography A, 2014, 1369, 52-63.	1.8	26
74	Population pharmacokinetic approach to evaluate the effect of *CYP2D6*, *CYP3A*, *ABCB1*, *POR* and *NR1I2* genotypes on donepezil clearance. British Journal of Clinical Pharmacology, 2014, 78, 135-144.	1.1	46
75	Quantitative monitoring of tamoxifen in human plasma extended to 40 metabolites using liquid-chromatography high-resolution mass spectrometry: new investigation capabilities for clinical pharmacology. Analytical and Bioanalytical Chemistry, 2014, 406, 2627-2640.	1.9	34
76	Tobramycin exposure from active calcium sulfate bone graft substitute. BMC Pharmacology & Toxicology, 2014, 15, 12.	1.0	7
77	Population Pharmacokinetics and Clinical Response for Artemether-Lumefantrine in Pregnant and Nonpregnant Women with Uncomplicated Plasmodium falciparum Malaria in Tanzania. Antimicrobial Agents and Chemotherapy, 2014, 58, 4583-4592.	1.4	37
78	Large-scale imatinib dose–concentration–effect study in CML patients under routine care conditions. Leukemia Research, 2014, 38, 764-772.	0.4	37
79	Risk perception by healthcare professionals related to drug use during pregnancy: a Swiss survey. Swiss Medical Weekly, 2014, 144, w13936.	0.8	20
80	Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients. Malaria Journal, 2013, 12, 235.	0.8	33
81	Population Pharmacokinetic Study of Memantine: Effects of Clinical and Genetic Factors. Clinical Pharmacokinetics, 2013, 52, 211-223.	1.6	41
82	Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours. British Journal of Clinical Pharmacology, 2013, 75, 1007-1018.	1.1	33
83	Benchmarking Therapeutic Drug Monitoring Software: A Review of Available Computer Tools. Clinical Pharmacokinetics, 2013, 52, 9-22.	1.6	141
84	Multiplex Liquid Chromatography-Tandem Mass Spectrometry Assay for Simultaneous Therapeutic Drug Monitoring of Ribavirin, Boceprevir, and Telaprevir. Antimicrobial Agents and Chemotherapy, 2013, 57, 3147-3158.	1.4	22
85	Systematic Review of Population Pharmacokinetic Analyses of Imatinib and Relationships With Treatment Outcomes. Therapeutic Drug Monitoring, 2013, 35, 150-167.	1.0	36
86	Relationship of CYP2D6, CYP3A, POR, and ABCB1 Genotypes With Galantamine Plasma Concentrations. Therapeutic Drug Monitoring, 2013, 35, 270-275.	1.0	27
87	Effect of Single Nucleotide Polymorphisms in Cytochrome P450 Isoenzyme and *N*-Acetyltransferase 2 Genes on the Metabolism of Artemisinin-Based Combination Therapies in Malaria Patients from Cambodia and Tanzania. Antimicrobial Agents and Chemotherapy, 2013, 57, 950-958.	1.4	51
88	Intraocular penetration of penciclovir after oral administration of famciclovir: a population pharmacokinetic model. Journal of Antimicrobial Chemotherapy, 2013, 68, 1635-1641.	1.3	3
89	Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels. Pharmacogenetics and Genomics, 2013, 23, 84-93.	0.7	41
90	Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals. Pharmacogenetics and Genomics, 2013, 23, 9-18.	0.7	25

#	Article	IF	Citations
91	Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals. Antimicrobial Agents and Chemotherapy, 2012, 56, 2959-2966.	1.4	39
92	Dosage Optimization of Treatments Using Population Pharmacokinetic Modeling and Simulation. Chimia, 2012, 66, 291-295.	0.3	8
93	Pregnancy Outcome Following Exposure to Topical Retinoids: A Multicenter Prospective Study. Journal of Clinical Pharmacology, 2012, 52, 1844-1851.	1.0	48
94	Therapeutic Drug Monitoring of Imatinib. Clinical Pharmacokinetics, 2012, 51, 187-201.	1.6	43
95	Challenging Recommended Oral and Intravenous Voriconazole Doses for Improved Efficacy and Safety: Population Pharmacokineticsâ€"Based Analysis of Adult Patients With Invasive Fungal Infections. Clinical Infectious Diseases, 2012, 55, 381-390.	2.9	178
96	Therapeutic Drug Monitoring of Targeted Anticancer Therapy. Tyrosine Kinase Inhibitors and Selective Estrogen Receptor Modulators: A Clinical Pharmacology Laboratory Perspective. , 2012, , 197-250.		2
97	Determinants of Sustained Viral Suppression in HIV-Infected Patients with Self-Reported Poor Adherence to Antiretroviral Therapy. PLoS ONE, 2012, 7, e29186.	1.1	21
98	Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 609-622.	1.5	15
99	Development and Validation of Decision Rules to Guide Frequency of Monitoring CD4 Cell Count in HIV-1 Infection before Starting Antiretroviral Therapy. PLoS ONE, 2011, 6, e18578.	1.1	16
100	ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenetics and Genomics, 2010, 20, 217-230.	0.7	104
101	Pharmacogenetics-Based Population Pharmacokinetic Analysis of Efavirenz in HIV-1-Infected Individuals. Clinical Pharmacology and Therapeutics, 2009, 85, 485-494.	2.3	113
102	In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenetics and Genomics, 2009, 19, 300-309.	0.7	133
103	ADME pathway approach for pharmacogenetic studies of anti-HIV therapy. Pharmacogenomics, 2007, 8, 623-633.	0.6	19
104	Pharmacokineticâ€"Pharmacodynamic Modelling: History and Perspectives. Journal of Pharmacokinetics and Pharmacodynamics, 2006, 33, 227-279.	0.8	147
105	Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents. Current HIV/AIDS Reports, 2006, 3, 118-125.	1.1	37
106	Population Pharmacokinetics of Atazanavir in Patients with Human Immunodeficiency Virus Infection. Antimicrobial Agents and Chemotherapy, 2006, 50, 3801-3808.	1.4	82
107	The Use of a Sum of Inverse Gaussian Functions to Describe the Absorption Profile of Drugs Exhibiting Complex Absorption. Pharmaceutical Research, 2005, 22, 1227-1235.	1.7	27
108	Mechanistic Pharmacokinetic and Pharmacodynamic Modeling of CHF3381 (2-[(2,3-Dihydro-1H-inden-2-yl)amino]acetamide Monohydrochloride), a Novel N-Methyl-d-aspartate Antagonist and Monoamine Oxidase-A Inhibitor in Healthy Subjects. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 647-657.	1.3	3

#	Article	IF	Citations
109	Population Pharmacokinetics of Indinavir in Patients Infected with Human Immunodeficiency Virus. Antimicrobial Agents and Chemotherapy, 2004, 48, 3226-3232.	1.4	36
110	Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients. Clinical Cancer Research, 2004, 10, 3728-3736.	3.2	403
111	Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clinical Pharmacology and Therapeutics, 2003, 73, 20-30.	2.3	231
112	Population Pharmacokinetic-Pharmacodynamic Modelling of Angiotensin Receptor Blockade in Healthy Volunteers. Clinical Pharmacokinetics, 2002, 41, 137-152.	1.6	18
113	Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients. European Journal of Clinical Pharmacology, 2001, 57, 723-727.	0.8	20